ArticlePLoS neglected tropical diseases2021
Evaluation of antigen-detecting and antibody-detecting diagnostic test combinations for diagnosing melioidosis.
Article in PLoS neglected tropical diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 13 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 1 synthesis or guideline pooled it, 22 citations in OpenAlex.
- Diagnostic accuracy of non-culture methods for the diagnosis of melioidosis: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Stability assessment of whole cell ELISA for Burkholderia pseudomallei antibodies detection.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Article
- Evidence of populational Burkholderia pseudomallei exposure in Madagascar.PLoS neglected tropical diseases · 2025Article
- Proteomic-based identification of novel EV-derived protein antibodies biomarkers for melioidosis diagnosis.PLoS neglected tropical diseases · 2025Article
- Performance of Antibody-Detection Tests for Human Melioidosis: A Systematic Review and Meta-analysis.The Malaysian journal of medical sciences : MJMS · 2024Review
- Diagnostic accuracy of DPP Fever Panel II Asia tests for tropical fever diagnosis.PLoS neglected tropical diseases · 2024Article
- Burkholderia pseudomallei and melioidosis.Nature reviews. Microbiology · 2024Review
- Development and evaluation of a multiplex serodiagnostic bead assay (BurkPx) for accurate melioidosis diagnosis.PLoS neglected tropical diseases · 2023Article
- Serodiagnosis of Abdominal Abscess Caused byInfection and drug resistance · 2023Article
- Sensitivity and specificity of DPP® Fever Panel II Asia in the diagnosis of malaria, dengue and melioidosis.Journal of medical microbiology · 2022Observational
- Correction: Evaluation of antigen-detecting and antibody-detecting diagnostic test combinations for diagnosing melioidosis.PLoS neglected tropical diseases · 2022Article
- Article
- What is the Role of Lateral Flow Immunoassay for the Diagnosis of Melioidosis?Open forum infectious diseases · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
13 authors at 5 institutions in 3 countries.
Funding
Abstract
backgroundMelioidosis, an infectious disease caused by Burkholderia pseudomallei, is endemic in many tropical developing countries and has a high mortality. Here we evaluated combinations of a lateral flow immunoassay (LFI) detecting B. pseudomallei capsular polysaccharide (CPS) and enzyme-linked immunosorbent assays (ELISA) detecting antibodies against hemolysin co-regulated protein (Hcp1) or O-polysaccharide (OPS) for diagnosing melioidosis. METHODOLOGY/PRINCIPAL
findingsWe conducted a cohort-based case-control study. Both cases and controls were derived from a prospective observational study of patients presenting with community-acquired infections and sepsis in northeast Thailand (Ubon-sepsis). Cases included 192 patients with a clinical specimen culture positive for B. pseudomallei. Controls included 502 patients who were blood culture positive for Staphylococcus aureus, Escherichia coli or Klebsiella pneumoniae or were polymerase chain reaction assay positive for malaria or dengue. Serum samples collected within 24 hours of admission were stored and tested using a CPS-LFI, Hcp1-ELISA and OPS-ELISA. When assessing diagnostic tests in combination, results were considered positive if either test was positive. We selected ELISA cut-offs corresponding to a specificity of 95%. Using a positive cut-off OD of 2.912 for Hcp1-ELISA, the combination of the CPS-LFI and Hcp1-ELISA had a sensitivity of 67.7% (130/192 case patients) and a specificity of 95.0% (477/502 control patients). The sensitivity of the combination (67.7%) was higher than that of the CPS-LFI alone (31.3%, p<0.001) and that of Hcp1-ELISA alone (53.6%, p<0.001). A similar phenomenon was also observed for the combination of CPS-LFI and OPS-ELISA. In case patients, positivity of the CPS-LFI was associated with a short duration of symptoms, high modified Sequential (sepsis-related) Organ Failure Assessment (SOFA) score, bacteraemia and mortality outcome, while positivity of Hcp1-ELISA was associated with a longer duration of symptoms, low modified SOFA score, non-bacteraemia and survival outcome. CONCLUSIONS/SIGNIFICANCE: A combination of antigen-antibody diagnostic tests increased the sensitivity of melioidosis diagnosis over individual tests while preserving high specificity. Point-of-care tests for melioidosis based on the use of combination assays should be further developed and evaluated.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.